Copyright Reports & Markets. All rights reserved.

Global Targeted Drugs for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Request for Sample of this report
Buy now

Table of Contents

    1 Targeted Drugs for Breast Cancer Market Overview

    • 1.1 Product Overview and Scope of Targeted Drugs for Breast Cancer
    • 1.2 Classification of Targeted Drugs for Breast Cancer by Types
      • 1.2.1 Global Targeted Drugs for Breast Cancer Revenue Comparison by Types (2019-2024)
      • 1.2.2 Global Targeted Drugs for Breast Cancer Revenue Market Share by Types in 2018
      • 1.2.3 HER-2 Targeted Drugs
      • 1.2.4 CDK4/6 Inhibitors
      • 1.2.5 PARP Targeted Drugs
      • 1.2.6 PI3K/AKT/mTor Pathway Inhibitors
      • 1.2.7 ER Targeted Drugs
      • 1.2.8 Aromatase Inhibitors
      • 1.2.9 Tubulin Inhibitors
      • 1.2.10 VEGF Targeted Drugs
      • 1.2.11 YTMS Targeted Drugs
      • 1.2.12 Other
    • 1.3 Global Targeted Drugs for Breast Cancer Market by Application
      • 1.3.1 Global Targeted Drugs for Breast Cancer Market Size and Market Share Comparison by Applications (2014-2024)
      • 1.3.2 Hospital
      • 1.3.3 Clinic
      • 1.3.4 Drug Center
      • 1.3.5 Other
    • 1.4 Global Targeted Drugs for Breast Cancer Market by Regions
      • 1.4.1 Global Targeted Drugs for Breast Cancer Market Size (Million USD) Comparison by Regions (2014-2024)
      • 1.4.1 North America (USA, Canada and Mexico) Targeted Drugs for Breast Cancer Status and Prospect (2014-2024)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Targeted Drugs for Breast Cancer Status and Prospect (2014-2024)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Targeted Drugs for Breast Cancer Status and Prospect (2014-2024)
      • 1.4.4 South America (Brazil, Argentina, Colombia) Targeted Drugs for Breast Cancer Status and Prospect (2014-2024)
      • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Targeted Drugs for Breast Cancer Status and Prospect (2014-2024)
    • 1.5 Global Market Size of Targeted Drugs for Breast Cancer (2014-2024)

    2 Manufacturers Profiles

    • 2.1 Roche
      • 2.1.1 Business Overview
      • 2.1.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 Roche Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.2 Teva
      • 2.2.1 Business Overview
      • 2.2.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 Teva Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.3 Mylan
      • 2.3.1 Business Overview
      • 2.3.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 Mylan Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.4 Hikma
      • 2.4.1 Business Overview
      • 2.4.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 Hikma Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.5 Hengrui Medicine
      • 2.5.1 Business Overview
      • 2.5.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 Hengrui Medicine Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.6 Cipla
      • 2.6.1 Business Overview
      • 2.6.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 Cipla Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.7 Reliance Group
      • 2.7.1 Business Overview
      • 2.7.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 Reliance Group Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.8 Hetero
      • 2.8.1 Business Overview
      • 2.8.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 Hetero Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.9 Pfizer
      • 2.9.1 Business Overview
      • 2.9.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.9.2.1 Product A
        • 2.9.2.2 Product B
      • 2.9.3 Pfizer Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.10 Eli Lilly
      • 2.10.1 Business Overview
      • 2.10.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.10.2.1 Product A
        • 2.10.2.2 Product B
      • 2.10.3 Eli Lilly Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.11 Novartis
      • 2.11.1 Business Overview
      • 2.11.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.11.2.1 Product A
        • 2.11.2.2 Product B
      • 2.11.3 Novartis Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.12 CANbridge
      • 2.12.1 Business Overview
      • 2.12.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.12.2.1 Product A
        • 2.12.2.2 Product B
      • 2.12.3 CANbridge Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.13 Puma Biotechnology
      • 2.13.1 Business Overview
      • 2.13.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.13.2.1 Product A
        • 2.13.2.2 Product B
      • 2.13.3 Puma Biotechnology Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.14 AstraZeneca
      • 2.14.1 Business Overview
      • 2.14.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.14.2.1 Product A
        • 2.14.2.2 Product B
      • 2.14.3 AstraZeneca Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.15 Chugai Pharmaceutical
      • 2.15.1 Business Overview
      • 2.15.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.15.2.1 Product A
        • 2.15.2.2 Product B
      • 2.15.3 Chugai Pharmaceutical Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.16 Eisai
      • 2.16.1 Business Overview
      • 2.16.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.16.2.1 Product A
        • 2.16.2.2 Product B
      • 2.16.3 Eisai Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.17 GlaxoSmithKline
      • 2.17.1 Business Overview
      • 2.17.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.17.2.1 Product A
        • 2.17.2.2 Product B
      • 2.17.3 GlaxoSmithKline Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.18 Bristol-Myers Squibb
      • 2.18.1 Business Overview
      • 2.18.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.18.2.1 Product A
        • 2.18.2.2 Product B
      • 2.18.3 Bristol-Myers Squibb Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.19 Otsuka Pharmaceutical
      • 2.19.1 Business Overview
      • 2.19.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.19.2.1 Product A
        • 2.19.2.2 Product B
      • 2.19.3 Otsuka Pharmaceutical Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.20 Merck
      • 2.20.1 Business Overview
      • 2.20.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.20.2.1 Product A
        • 2.20.2.2 Product B
      • 2.20.3 Merck Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.21 BioMarin
      • 2.21.1 Business Overview
      • 2.2.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.21.2.1 Product A
        • 2.21.2.2 Product B
      • 2.21.3 BioMarin Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.22 Hengrui Pharmaceutical
      • 2.22.1 Business Overview
      • 2.22.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.22.2.1 Product A
        • 2.22.2.2 Product B
      • 2.22.3 Hengrui Pharmaceutical Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.23 Beijing Biostar Technologies
      • 2.23.1 Business Overview
      • 2.23.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.23.2.1 Product A
        • 2.23.2.2 Product B
      • 2.23.3 Beijing Biostar Technologies Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.24 Bayer
      • 2.24.1 Business Overview
      • 2.24.2 Targeted Drugs for Breast Cancer Type and Applications
        • 2.24.2.1 Product A
        • 2.24.2.2 Product B
      • 2.24.3 Bayer Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

    3 Global Targeted Drugs for Breast Cancer Market Competition, by Players

    • 3.1 Global Targeted Drugs for Breast Cancer Revenue and Share by Players (2014-2019)
    • 3.2 Market Concentration Rate
      • 3.2.1 Top 5 Targeted Drugs for Breast Cancer Players Market Share
      • 3.2.2 Top 10 Targeted Drugs for Breast Cancer Players Market Share
    • 3.3 Market Competition Trend

    4 Global Targeted Drugs for Breast Cancer Market Size by Regions

    • 4.1 Global Targeted Drugs for Breast Cancer Revenue and Market Share by Regions
    • 4.2 North America Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 4.3 Europe Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 4.4 Asia-Pacific Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 4.5 South America Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 4.6 Middle East and Africa Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

    5 North America Targeted Drugs for Breast Cancer Revenue by Countries

    • 5.1 North America Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
    • 5.2 USA Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 5.3 Canada Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 5.4 Mexico Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

    6 Europe Targeted Drugs for Breast Cancer Revenue by Countries

    • 6.1 Europe Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
    • 6.2 Germany Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 6.3 UK Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 6.4 France Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 6.5 Russia Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 6.6 Italy Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

    7 Asia-Pacific Targeted Drugs for Breast Cancer Revenue by Countries

    • 7.1 Asia-Pacific Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
    • 7.2 China Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 7.3 Japan Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 7.4 Korea Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 7.5 India Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 7.6 Southeast Asia Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

    8 South America Targeted Drugs for Breast Cancer Revenue by Countries

    • 8.1 South America Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
    • 8.2 Brazil Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 8.3 Argentina Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 8.4 Colombia Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

    9 Middle East and Africa Revenue Targeted Drugs for Breast Cancer by Countries

    • 9.1 Middle East and Africa Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
    • 9.2 Saudi Arabia Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 9.3 UAE Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 9.4 Egypt Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 9.5 Nigeria Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 9.6 South Africa Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

    10 Global Targeted Drugs for Breast Cancer Market Segment by Type

    • 10.1 Global Targeted Drugs for Breast Cancer Revenue and Market Share by Type (2014-2019)
    • 10.2 Global Targeted Drugs for Breast Cancer Market Forecast by Type (2019-2024)
    • 10.3 HER-2 Targeted Drugs Revenue Growth Rate (2014-2024)
    • 10.4 CDK4/6 Inhibitors Revenue Growth Rate (2014-2024)
    • 10.5 PARP Targeted Drugs Revenue Growth Rate (2014-2024)
    • 10.6 PI3K/AKT/mTor Pathway Inhibitors Revenue Growth Rate (2014-2024)
    • 10.7 ER Targeted Drugs Revenue Growth Rate (2014-2024)
    • 10.8 Aromatase Inhibitors Revenue Growth Rate (2014-2024)
    • 10.9 Tubulin Inhibitors Revenue Growth Rate (2014-2024)
    • 10.10 VEGF Targeted Drugs Revenue Growth Rate (2014-2024)
    • 10.11 YTMS Targeted Drugs Revenue Growth Rate (2014-2024)
    • 10.12 Other Revenue Growth Rate (2014-2024)

    11 Global Targeted Drugs for Breast Cancer Market Segment by Application

    • 11.1 Global Targeted Drugs for Breast Cancer Revenue Market Share by Application (2014-2019)
    • 11.2 Targeted Drugs for Breast Cancer Market Forecast by Application (2019-2024)
    • 11.3 Hospital Revenue Growth (2014-2019)
    • 11.4 Clinic Revenue Growth (2014-2019)
    • 11.5 Drug Center Revenue Growth (2014-2019)
    • 11.6 Other Revenue Growth (2014-2019)

    12 Global Targeted Drugs for Breast Cancer Market Size Forecast (2019-2024)

    • 12.1 Global Targeted Drugs for Breast Cancer Market Size Forecast (2019-2024)
    • 12.2 Global Targeted Drugs for Breast Cancer Market Forecast by Regions (2019-2024)
    • 12.3 North America Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
    • 12.4 Europe Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
    • 12.5 Asia-Pacific Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
    • 12.6 South America Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
    • 12.7 Middle East and Africa Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Methodology

      Scope of the Report:
      The global Targeted Drugs for Breast Cancer market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
      The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
      North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Targeted Drugs for Breast Cancer.
      Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
      This report studies the Targeted Drugs for Breast Cancer market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Targeted Drugs for Breast Cancer market by product type and applications/end industries.

      Market Segment by Companies, this report covers
      Roche
      Teva
      Mylan
      Hikma
      Hengrui Medicine
      Cipla
      Reliance Group
      Hetero
      Pfizer
      Eli Lilly
      Novartis
      CANbridge
      Puma Biotechnology
      AstraZeneca
      Chugai Pharmaceutical
      Eisai
      GlaxoSmithKline
      Bristol-Myers Squibb
      Otsuka Pharmaceutical
      Merck
      BioMarin
      Hengrui Pharmaceutical
      Beijing Biostar Technologies
      Bayer

      Market Segment by Regions, regional analysis covers
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, Colombia)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers
      HER-2 Targeted Drugs
      CDK4/6 Inhibitors
      PARP Targeted Drugs
      PI3K/AKT/mTor Pathway Inhibitors
      ER Targeted Drugs
      Aromatase Inhibitors
      Tubulin Inhibitors
      VEGF Targeted Drugs
      YTMS Targeted Drugs
      Other

      Market Segment by Applications, can be divided into
      Hospital
      Clinic
      Drug Center
      Other

      Buy now